Don’t miss the latest developments in business and finance.

Alembic Pharmaceuticals receives USFDA approval for Clomipramine Hydrochloride Capsules

Image
Capital Market
Last Updated : Aug 05 2021 | 12:16 PM IST
Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg, and 75 mg.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Anafranil Capsules, 25 mg, 50 mg, and 75 mg, of SpecGX LLC.

Clomipramine Hydrochloride Capsules are indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD).

Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg, and 75 mg, have an estimated market size of US$ 32 million for twelve months ending June 2021 according to IQVIA.

Alembic has a cumulative total of 149 ANDA approvals (131 final approvals and 18 tentative approvals) from USFDA.

Powered by Capital Market - Live News

Also Read

First Published: Aug 05 2021 | 11:59 AM IST

Next Story